Supplementary Materials

Supplementary Material for:

Targeting LGR5+ cells with an antibody-drug conjugate for the treatment of colon cancer

Melissa R. Junttila,* Weiguang Mao, Xi Wang, Bu-Er Wang, Thinh Pham, John Flygare, Shang-Fan Yu, Sharon Yee, David Goldenberg, Carter Fields, Jeffrey Eastham-Anderson, Mallika Singh, Rajesh Vij, Jo-Anne Hongo, Ron Firestein, Melissa Schutten, Kelly Flagella, Paul Polakis, Andrew G. Polson*

*Corresponding author. E-mail: polson{at}gene.com (A.G.P.); junttila.melissa{at}gene.com (M.R.J.)

Published 18 November 2015, Sci. Transl. Med. 7, 314ra186 (2015)
DOI: 10.1126/scitranslmed.aac7433

This PDF file includes:

  • Materials and Methods
  • Fig. S1. LGR5 expression analysis in human tissue.
  • Fig. S2. Lgr5 expression in mouse and rat tissue.
  • Fig. S3. LGR5 expression in human CRC tumors.
  • Fig. S4. ISH and IHC for LGR5 in human CRC.
  • Fig. S5. Specific binding of anti-LGR5.
  • Fig. S6. Effect of anti-LGR5 antibody on RSPO binding and Wnt activation.
  • Fig. S7. LGR5 expression in xenograft models.
  • Fig. S8. Safety assessment of anti-LGR5 ADCs.
  • Fig. S9. Anti-LGR5 ADC treatment in the AKV model.
  • Fig. S10. Unconjugated anti-LGR5 antibody treatment in the AKV model.
  • Table S2. IHC scoring guidelines for LGR5.
  • Table S3. LGR5 IHC summary for overall IHC score.

[Download PDF]

Other Supplementary Material for this manuscript includes the following:

  • Table S1. Affymetrix data for LGR5 in human tissue and cancer (provided as an Excel file).
  • Table S4. Response data for anti-LGR5 ADC treatment of human xenograft models (provided as an Excel file).

[Download Tables S1 and S4]